Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

170.88 -0.62 (-0.36%)
Streaming Delayed Price Updated: 9:40 AM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
56 57 Next >
News headline image
Market Currents: Why Pick Stocks? ↗
Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and... 
Via Talk Markets
News headline image
2 Stocks Near 52-Week Highs That Could Climb Higher ↗
This pair of stocks are bucking the trend and they could climb even higher. 
Via The Motley Fool
CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention
The market has experienced some relief from bearish price action in November, continuing October’s push to usher the SPDR S&P 500 ETF (NYSEARCA: SPY) toward $400. 
Via TheNewswire.com
Topics ETFs Economy Stocks
News headline image
CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention
By Jad Malaeb, Benzinga 
Via News Direct
Topics ETFs Economy
News headline image
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
News headline image
Elliott Wave Technical Analysis: Biogen Inc. - Thursday, Nov. 10 ↗
Looking for a clear three-wave move pullback before considering any long-term longs. 
Via Talk Markets
News headline image
Is Biogen Poised for a Bull Run? ↗
Biogen has been a market-beating stock this year, but can that trend continue? 
Via The Motley Fool
News headline image
CBOE's Weekly Market Recap: Nov.14-18 – Biogen's Alzheimer's Drug Captures Investors' Attention ↗
The market has experienced some relief from bearish price action in November, continuing October’s push to usher the SPDR S&P 500 ETF (NYSEARCA: SPY) toward $400. 
Via Benzinga
News headline image
Not All Offices Are Created Equal… You Can Profit From One Sector That’s Poised to See Demand Growth ↗
Despite what we might see in the upcoming year with office real estate or specific companies within the life sciences industry, REITs with exposure to in-demand properties remain a great way to earn... 
Via Talk Markets
News headline image
TEVA Stock Alert: What to Know About Teva Pharmaceuticals’ New CEO ↗
Teva Pharmaceuticals (TEVA) stock is sliding on Monday after the company announced Richard Francis as its newest president and CEO. 
Via InvestorPlace
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
3 Stocks to Avoid Right Now ↗
Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective. 
Via The Motley Fool
News headline image
CONTINUED INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Continues to Investigate Biogen Inc.’s Directors and Officers for Breach of Fiduciary Duties – BIIB
From Scott+Scott Attorneys at Law LLP
Via Business Wire
News headline image
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
News headline image
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage ↗
 
Via Benzinga
News headline image
Why Is Cassava Sciences (SAVA) Stock Up Today? ↗
Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever. 
Via InvestorPlace
News headline image
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers ↗
 
Via Benzinga
News headline image
Why Is AST SpaceMobile (ASTS) Moving Today? ↗
AST SpaceMobile (ASTS) stock is a hot topic on Monday as investors react to the company setting up its BlueWalker 3 satellite array. 
Via InvestorPlace
News headline image
Why Is Biogen (BIIB) Stock Up Today? ↗
Biogen (BIIB) stock is rising higher on Monday after Roche's (RHHBY) Alzheimer's drug didn't perform well in a clinical trial. 
Via InvestorPlace
News headline image
What's Going On With Biogen Stock Today? ↗
Biogen Inc (NASDAQ: BIIB) shares are trading higher Monday after competitor Roche's Alzheimer's candidate did not meet its primary endpoint in recent studies. 
Via Benzinga
News headline image
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others ↗
Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map. 
Via Investor's Business Daily
News headline image
Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus ↗
The major U.S. index futures are pointing to a moderately lower opening on Wall Street on Monday, as optimism following a tamer inflation data gives way to apprehension. The yield on the benchmark... 
Via Benzinga
News headline image
Why Shares Of Eli Lilly And Biogen Are Rallying Today ↗
Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday despite the negative broader market sentiment. 
Via Benzinga
News headline image
Why Are Healthcare Stocks Down Today? ↗
Healthcare stocks are falling after a false tweet from a Twitter account impersonating Eli Lilly. Here's what this news means for investors. 
Via InvestorPlace
News headline image
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles ↗
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
News headline image
Biogen Names Christopher Viehbacher President and Chief Executive Officer
Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies 
From Biogen Inc.
Via GlobeNewswire
News headline image
The Power of McKinsey ↗
Author Michael Forsythe talks about his new book, "When McKinsey Comes to Town: The Hidden Influence of the World's Most Powerful Consulting Firm." 
Via The Motley Fool
News headline image
Biogen To Rally Around 15%? Here Are 5 Other Price Target Changes For Tuesday ↗
Mizuho raised Biogen Inc. (NASDAQ: BIIB) price target from $270 to $325. Mizuho analyst Salim Syed maintained the stock with a Buy rating. Biogen shares fell 0.3% to close at $283.44 on Monday. 
Via Benzinga
News headline image
Don't Get Used to Lower Medicare Part B Premiums -- Here's Why ↗
Medicare might have to begin paying billions of extra dollars for new drugs in the not-too-distant future. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.